reviewCancer Treatment ReviewsNov 27, 2016Closed access

Resistance to PD1/PDL1 checkpoint inhibition

JSJake S. O’Donnell GVGeorgina V. Long RARichard A. Scolyer MWMichele W.L. Teng MJMark J. Smyth

University of Queensland · QIMR Berghofer Medical Research Institute · +3 more institutions

Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

594

total citations

FWCI: 22.95
Percentile: 100%
References: 115

Citations per year

Authors

5

JS
Jake S. O’DonnellCorresponding
University of Queensland, QIMR Berghofer Medical Research Institute
GV
Georgina V. Long
University of Sydney, Melanoma Institute Australia
RA
Richard A. Scolyer
Royal Prince Alfred Hospital, University of Sydney, Melanoma Institute Australia
MW
Michele W.L. Teng
QIMR Berghofer Medical Research Institute
MJ
Mark J. Smyth
University of Queensland, QIMR Berghofer Medical Research Institute

Topics & keywords

Topics

Keywords

Medicine
Ipilimumab
Pembrolizumab
Immunotherapy
Clinical trial
Disease
Nivolumab
Tumor microenvironment

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.